| Identification | Back Directory | [Name]
BT11 | [CAS]
1912399-75-7 | [Synonyms]
BT11
BT11;BT 11
BT-11, >98%
Methanone, 1,1'-(1,4-piperazinediyl)bis[1-[6-(1H-benzimidazol-2-yl)-2-pyridinyl]-
[4-[6-(1~{H}-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1~{H}-benzimidazol-2-yl)pyridin-2-yl]methanone | [Molecular Formula]
C30H24N8O2 | [MOL File]
1912399-75-7.mol | [Molecular Weight]
528.56 |
| Chemical Properties | Back Directory | [Boiling point ]
923.4±75.0 °C(Predicted) | [density ]
1.424±0.06 g/cm3(Predicted) | [solubility ]
DMSO: Soluble: =10 mg/ml | [form ]
Solid | [pka]
10.24±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
BT-11 is an orally available LANCL2 binding compound for treating inflammatory bowel disease. | [Biological Activity]
BT11 is an orally active compound that binds to lanthionine synthetase C-like 2 (LANCL2) with a Kd value of 7.7 μM and can be used for the treatment of inflammatory bowel disease. | [in vivo]
Oral administration of 8 mg/kg/day BT-11 to mice attenuates colitis. In the drug safety testing experiment in rats, oral high concentrations of BT-11 have good safety (detection concentration up to 1000 mg/kg/day). | [target]
| Target | Value | LANCL2
() | [References]
[1] Carbo A, et al. An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease. J Med Chem. 2016 Nov 23;59(22):10113-10126. DOI:10.1021/acs.jmedchem.6b00412
[2] Bissel P, et al. Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn's Disease. Int J Toxicol. 2016 Sep;35(5):521-9. DOI:10.1177/1091581816646356 |
|
|
|
Tags:1912399-75-7
Related Product Information
|
|
1912399-75-7
2863688-23-5
84484-78-6
1142363-52-7
203191-10-0
1258453-75-6
|
|